Every material Form 8-K Arbutus Biopharma Corp has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Arbutus Biopharma announced that the U.S. Food and Drug Administration removed the clinical hold on the Investigational New Drug application for AB-101, its oral PD-L1 inhibitor for chronic hepatitis B. The company may now engage in additional clinical development of AB-101 in the United States and says it is evaluating next steps.
FDA removed the clinical hold on the IND application for AB-101, announced October 22, 2026
AB-101 completed a Phase 1a/1b trial, which the company says was generally well-tolerated
Trial data showed high receptor occupancy in seven chronic HBV patients and hepatitis B surface antigen decline in two patients at the 30mg dose
Arbutus Biopharma announced plans for a modified Dutch auction tender offer to buy back up to $230 million of its common shares, at $5.00 to $5.75 per share, funded from cash on hand. The offer has not yet commenced and is subject to exemptive relief, so its terms and completion are not assured, but it would return proceeds from the Moderna settlement to shareholders.
Offer to repurchase up to $230 million of common shares at not less than $5.00 and not more than $5.75 per share, in cash
Expected to commence on or about August 24, 2026, and expire on or about September 29, 2026, unless extended or terminated
Funded through the company's cash on hand; commencement depends on obtaining exemptive relief under Canadian and US securities laws
Follows the March 2026 Moderna settlement and a July 2026 initial payment under that settlement
Arbutus Biopharma reported second-quarter 2026 results showing total revenue of $1.0 million and a net loss of $5.1 million, compared with $10.7 million of revenue and net income of $2.5 million a year earlier. The company received $178.4 million from its Moderna settlement in July and plans to return up to about $230 million to shareholders through share repurchases starting in the third quarter, though the board has not yet approved the form and no assurance is given that repurchases will occur.
Q2 2026 total revenue was $1.0 million, versus $10.7 million in Q2 2025, which included $9.6 million of previously deferred revenue recognized on the Qilu partnership conclusion.
Q2 2026 net loss was $5.1 million, or $0.03 per share, compared with net income of $2.5 million, or $0.01 per share, in Q2 2025.
On July 8, 2026, the company received $178.4 million as its share of the Moderna noncontingent settlement payment.
Cash, cash equivalents and marketable securities were $92.6 million as of June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arbutus Biopharma Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →